Loading...

Utah Medical Products

Nasdaq:UTMD
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UTMD
Nasdaq
$326M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry in the United States, Europe, and internationally. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
UTMD Share Price and Events
7 Day Returns
2.6%
NasdaqGS:UTMD
-5.3%
US Medical Equipment
-0.1%
US Market
1 Year Returns
-18.4%
NasdaqGS:UTMD
12.4%
US Medical Equipment
7.6%
US Market
UTMD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Utah Medical Products (UTMD) 2.6% 8.7% 0.5% -18.4% 38.1% 67.4%
US Medical Equipment -5.3% -5.8% 2.1% 12.4% 49.3% 90.1%
US Market -0.1% 3.7% 10.2% 7.6% 38.1% 46.4%
1 Year Return vs Industry and Market
  • UTMD underperformed the Medical Equipment industry which returned 12.4% over the past year.
  • UTMD underperformed the Market in United States of America which returned 7.6% over the past year.
Price Volatility
UTMD
Industry
5yr Volatility vs Market
Related Companies

UTMD Value

 Is Utah Medical Products undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Utah Medical Products to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Utah Medical Products.

NasdaqGS:UTMD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:UTMD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.928 (1 + (1- 21%) (0%))
0.952
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.952 * 5.96%)
8.4%

Discounted Cash Flow Calculation for NasdaqGS:UTMD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Utah Medical Products is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:UTMD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.4%)
2019 15.08 Est @ 0.36% 13.91
2020 15.24 Est @ 1.07% 12.97
2021 15.48 Est @ 1.57% 12.15
2022 15.77 Est @ 1.92% 11.42
2023 16.11 Est @ 2.16% 10.77
2024 16.49 Est @ 2.33% 10.16
2025 16.89 Est @ 2.45% 9.60
2026 17.32 Est @ 2.53% 9.08
2027 17.77 Est @ 2.59% 8.60
2028 18.24 Est @ 2.63% 8.14
Present value of next 10 years cash flows $106.80
NasdaqGS:UTMD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $18.24 × (1 + 2.73%) ÷ (8.4% – 2.73%)
$330.34
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $330.34 ÷ (1 + 8.4%)10
$147.43
NasdaqGS:UTMD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $106.80 + $147.43
$254.23
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $254.23 / 3.72
$68.29
NasdaqGS:UTMD Discount to Share Price
Calculation Result
Value per share (USD) From above. $68.29
Current discount Discount to share price of $87.50
= -1 x ($87.50 - $68.29) / $68.29
-28.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Utah Medical Products is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Utah Medical Products's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Utah Medical Products's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:UTMD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $4.97
NasdaqGS:UTMD Share Price ** NasdaqGS (2019-04-23) in USD $87.5
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 38.8x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 18.03x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Utah Medical Products.

NasdaqGS:UTMD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:UTMD Share Price ÷ EPS (both in USD)

= 87.5 ÷ 4.97

17.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Utah Medical Products is good value based on earnings compared to the US Medical Equipment industry average.
  • Utah Medical Products is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Utah Medical Products's expected growth come at a high price?
Raw Data
NasdaqGS:UTMD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 17.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
-7%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 54 Publicly-Listed Medical Equipment Companies 2.3x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.55x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Utah Medical Products, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Utah Medical Products's assets?
Raw Data
NasdaqGS:UTMD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $23.92
NasdaqGS:UTMD Share Price * NasdaqGS (2019-04-23) in USD $87.5
United States of America Medical Equipment Industry PB Ratio Median Figure of 184 Publicly-Listed Medical Equipment Companies 4.14x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqGS:UTMD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:UTMD Share Price ÷ Book Value per Share (both in USD)

= 87.5 ÷ 23.92

3.66x

* Primary Listing of Utah Medical Products.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Utah Medical Products is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Utah Medical Products's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Utah Medical Products has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

UTMD Future Performance

 How is Utah Medical Products expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Utah Medical Products, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Utah Medical Products expected to grow at an attractive rate?
  • Utah Medical Products's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Utah Medical Products's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • Unable to compare Utah Medical Products's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:UTMD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:UTMD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts -7%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 20.8%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:UTMD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:UTMD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 42 17 19
2018-09-30 42 17 13
2018-06-30 42 17 10
2018-03-31 42 16 9
2017-12-31 41 17 9
2017-09-30 40 16 14
2017-06-30 40 15 13
2017-03-31 39 15 12
2016-12-31 39 15 12
2016-09-30 40 15 13
2016-06-30 40 16 13
2016-03-31 40 16 12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Utah Medical Products's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if Utah Medical Products is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:UTMD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Utah Medical Products Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:UTMD Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 4.97
2018-09-30 3.39
2018-06-30 2.55
2018-03-31 2.44
2017-12-31 2.29
2017-09-30 3.69
2017-06-30 3.50
2017-03-31 3.33
2016-12-31 3.23
2016-09-30 3.36
2016-06-30 3.39
2016-03-31 3.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Utah Medical Products will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Utah Medical Products's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Utah Medical Products has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

UTMD Past Performance

  How has Utah Medical Products performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Utah Medical Products's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Utah Medical Products's year on year earnings growth rate has been positive over the past 5 years.
  • Utah Medical Products's 1-year earnings growth exceeds its 5-year average (118.2% vs 2.2%)
  • Utah Medical Products's earnings growth has exceeded the US Medical Equipment industry average in the past year (118.2% vs 32.8%).
Earnings and Revenue History
Utah Medical Products's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Utah Medical Products Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:UTMD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 42.00 18.56 7.16 0.45
2018-09-30 42.44 12.64 7.20 0.44
2018-06-30 42.18 9.50 7.13 0.44
2018-03-31 42.04 9.06 7.05 0.44
2017-12-31 41.41 8.51 6.91 0.45
2017-09-30 40.07 13.74 6.80 0.45
2017-06-30 39.60 13.06 6.79 0.48
2017-03-31 39.26 12.45 6.87 0.48
2016-12-31 39.30 12.13 6.97 0.48
2016-09-30 39.96 12.62 7.25 0.48
2016-06-30 40.17 12.73 7.52 0.46
2016-03-31 40.01 12.39 7.69 0.48
2015-12-31 39.87 11.84 7.97 0.52
2015-09-30 40.53 11.63 7.94 0.51
2015-06-30 41.31 11.41 8.06 0.52
2015-03-31 41.40 11.32 8.24 0.49
2014-12-31 41.00 11.38 8.24 0.46
2014-09-30 40.84 11.85 8.57 0.47
2014-06-30 40.01 11.59 8.65 0.49
2014-03-31 39.59 11.39 8.69 0.49
2013-12-31 40.20 11.41 8.87 0.49
2013-09-30 40.02 10.20 8.71 0.50
2013-06-30 40.70 10.35 8.93 0.51
2013-03-31 40.72 10.12 9.09 0.54
2012-12-31 41.55 10.17 9.30 0.56
2012-09-30 41.63 9.77 9.86 0.57
2012-06-30 41.92 9.29 10.32 0.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Utah Medical Products has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Utah Medical Products used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • Utah Medical Products's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Utah Medical Products's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Utah Medical Products has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

UTMD Health

 How is Utah Medical Products's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Utah Medical Products's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Utah Medical Products is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Utah Medical Products's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Utah Medical Products's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Utah Medical Products has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Utah Medical Products Company Filings, last reported 3 months ago.

NasdaqGS:UTMD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 88.99 0.00 51.11
2018-09-30 88.83 0.00 49.35
2018-06-30 83.36 0.00 45.87
2018-03-31 82.69 0.00 42.93
2017-12-31 78.12 0.00 39.96
2017-09-30 81.20 0.00 37.52
2017-06-30 77.25 0.00 33.81
2017-03-31 72.54 0.00 30.74
2016-12-31 69.24 0.00 26.36
2016-09-30 72.67 0.00 31.61
2016-06-30 71.07 0.00 29.44
2016-03-31 71.66 0.00 27.56
2015-12-31 69.65 0.00 23.33
2015-09-30 68.35 0.00 21.68
2015-06-30 68.19 0.00 19.23
2015-03-31 63.84 0.00 16.16
2014-12-31 64.56 4.87 19.33
2014-09-30 64.22 5.99 18.30
2014-06-30 64.97 7.24 15.99
2014-03-31 62.94 8.14 15.09
2013-12-31 60.58 9.12 14.45
2013-09-30 57.08 9.97 13.92
2013-06-30 52.64 10.54 11.44
2013-03-31 50.72 11.49 10.92
2012-12-31 50.97 13.00 8.91
2012-09-30 48.71 14.87 9.37
2012-06-30 45.55 16.56 7.98
  • Utah Medical Products has no debt.
  • Utah Medical Products has no debt compared to 5 years ago when it was 15%.
  • Utah Medical Products has no debt, it does not need to be covered by operating cash flow.
  • Utah Medical Products has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Utah Medical Products's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Utah Medical Products has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

UTMD Dividends

 What is Utah Medical Products's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.26%
Current annual income from Utah Medical Products dividends.
If you bought $2,000 of Utah Medical Products shares you are expected to receive $25 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Utah Medical Products's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.4%).
  • Utah Medical Products's dividend is below the markets top 25% of dividend payers in United States of America (3.64%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:UTMD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:UTMD Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-02-12 1.100 1.267
2018-10-30 1.100 1.254
2018-07-31 1.080 1.184
2018-05-08 1.080 1.035
2018-02-13 1.080 1.124
2017-10-31 1.080 1.318
2017-08-01 1.060 1.447
2017-05-09 1.060 1.533
2017-02-07 1.060 1.718
2016-11-01 1.060 1.601
2016-08-03 1.040 1.678
2016-05-04 1.040 1.598
2016-02-10 1.040 1.689
2015-11-03 1.040 1.810
2015-02-03 1.020 1.821
2014-11-04 1.020 1.759
2014-07-31 1.000 1.957
2014-05-06 1.000 1.981
2014-02-11 1.000 1.843
2013-10-29 1.000 1.865
2013-07-30 0.980 1.813
2013-05-07 0.980 1.916
2013-02-12 0.980 2.175
2012-11-08 0.980 2.631
2012-07-31 0.960 2.837
2012-05-08 0.960 2.867
2012-02-07 0.960 3.141
2011-11-01 0.960 3.473
2011-08-02 0.940 3.592
2011-05-10 0.940 3.548
2011-02-01 0.940 3.390
2011-01-27 0.940 3.491
2010-08-03 0.940 3.423
2010-04-29 0.940 3.594
2010-02-02 0.940 3.375
2009-11-03 0.940 3.253
2009-08-04 0.920 3.201
2009-05-05 0.920 3.676
2009-04-24 0.920 4.191

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Utah Medical Products's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (4.6x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Utah Medical Products's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Utah Medical Products afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Utah Medical Products has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

UTMD Management

 What is the CEO of Utah Medical Products's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kevin Cornwell
COMPENSATION $501,180
AGE 71
TENURE AS CEO 26.3 years
CEO Bio

Mr. Kevin L. Cornwell has been the Chairman of the Board at Utah Medical Products Inc. since 1996 and its President and Chief Executive Officer since December 1992. Mr. Cornwell has been Secretary of Utah Medical Products Inc. since 1993 and its Director since 1993. He has served in various senior operating management positions in several technology-based companies over a 30-year time span, including as a Director on seven other company boards. He received B.S. degree in Chemical Engineering from Stanford University, M.S. degree in Management Science from the Stanford Graduate School of Engineering and M.B.A. degree specializing in finance from the Stanford Graduate School of Business.

CEO Compensation
  • Kevin's compensation has been consistent with company performance over the past year.
  • Kevin's remuneration is lower than average for companies of similar size in United States of America.
Management Team

Kevin Cornwell

TITLE
Chairman
COMPENSATION
$501K
AGE
71
TENURE
26.3 yrs

Brian Koopman

TITLE
Principal Financial Officer & Controller
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Utah Medical Products board of directors in years:

21.8
Average Tenure
71
Average Age
  • The average tenure for the Utah Medical Products board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Kevin Cornwell

TITLE
Chairman
COMPENSATION
$501K
AGE
71
TENURE
23.3 yrs

Ernst Hoyer

TITLE
Lead Director
COMPENSATION
$32K
AGE
80

Paul Richins

TITLE
Director
COMPENSATION
$147K
AGE
58
TENURE
21.3 yrs

Barbara Payne

TITLE
Director
COMPENSATION
$25K
AGE
71
TENURE
22.3 yrs

James Beeson

TITLE
Independent Director
COMPENSATION
$25K
AGE
76
TENURE
12.2 yrs
Who owns this company?
Recent Insider Trading
  • Utah Medical Products insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
28. Feb 19 Sell Barbara Payne Individual 26. Feb 19 26. Feb 19 -4 $89.00 $-356
28. Feb 19 Sell Barbara Payne Individual 27. Feb 19 27. Feb 19 -1,521 $85.75 $-130,426
22. Feb 19 Sell Barbara Payne Individual 20. Feb 19 20. Feb 19 -1 $92.00 $-92
16. Feb 19 Sell Barbara Payne Individual 14. Feb 19 14. Feb 19 -23 $92.50 $-2,128
16. Feb 19 Sell Barbara Payne Individual 13. Feb 19 15. Feb 19 -2,445 $92.29 $-225,621
28. Nov 18 Sell Barbara Payne Individual 27. Nov 18 27. Nov 18 -3 $95.00 $-285
28. Nov 18 Sell Barbara Payne Individual 28. Nov 18 28. Nov 18 -1,097 $93.79 $-102,889
30. Jul 18 Sell Barbara Payne Individual 27. Jul 18 27. Jul 18 -1,500 $96.00 $-144,000
15. Jun 18 Sell Kevin Cornwell Individual 14. Jun 18 15. Jun 18 -8,080 $107.71 $-865,132
13. Jun 18 Sell Kevin Cornwell Individual 11. Jun 18 12. Jun 18 -3,967 $105.23 $-417,429
07. Jun 18 Sell Kevin Cornwell Individual 05. Jun 18 05. Jun 18 -5,714 $105.00 $-599,970
04. Jun 18 Sell Kevin Cornwell Individual 31. May 18 01. Jun 18 -2,239 $105.17 $-235,379
22. May 18 Sell Ernst Hoyer Individual 18. May 18 18. May 18 -6,550 $104.03 $-681,364
15. May 18 Sell Ernst Hoyer Individual 11. May 18 11. May 18 -84 $104.00 $-8,736
10. May 18 Sell Ernst Hoyer Individual 07. May 18 09. May 18 -1,614 $104.44 $-168,525
09. May 18 Sell Barbara Payne Individual 07. May 18 07. May 18 -2,406 $104.56 $-251,569
07. May 18 Sell Ernst Hoyer Individual 03. May 18 04. May 18 -1,752 $104.10 $-182,272
X
Management checks
We assess Utah Medical Products's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Utah Medical Products has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

UTMD News

Simply Wall St News

Do Utah Medical Products's (NASDAQ:UTMD) Earnings Warrant Your Attention?

In contrast to all that, I prefer to spend time on companies like Utah Medical Products (NASDAQ:UTMD), which has not only revenues, but also profits. … I like to see top-line growth as an indication that growth is sustainable, and I look for a high earnings before interest and taxation (EBIT) margin to point to a competitive moat (though some companies with low margins also have moats). … It seems Utah Medical Products is pretty stable, since revenue and EBIT margins are pretty flat year on year.

Simply Wall St -

What Can We Make Of Utah Medical Products, Inc.’s (NASDAQ:UTMD) High Return On Capital?

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … Return On Capital Employed (ROCE): What is it? … How Do You Calculate Return On Capital Employed

Simply Wall St -

Should You Be Pleased About The CEO Pay At Utah Medical Products, Inc.'s (NASDAQ:UTMD)

First, this article will compare CEO compensation with compensation at similar sized companies. … has a market capitalization of US$317m, and pays its CEO total annual compensation worth US$501k. … While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$156k

Simply Wall St -

Is Utah Medical Products, Inc.'s (NASDAQ:UTMD) P/E Ratio Really That Good?

We'll look at Utah Medical Products, Inc.'s (NASDAQ:UTMD) P/E ratio and reflect on what it tells us about the company's share price. … Utah Medical Products has a price to earnings ratio of 17.59, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

Should You Be Excited About Utah Medical Products, Inc.'s (NASDAQ:UTMD) 21% Return On Equity?

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Utah Medical Products, Inc. … That means that for every $1 worth of shareholders' equity, it generated $0.21 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Utah Medical Products, Inc. (NASDAQ:UTMD): Time For A Financial Health Check

(NASDAQ:UTMD), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is UTMD will have to adhere to stricter debt covenants and have less financial flexibility. … Is UTMD growing fast enough to value financial flexibility over lower cost of capital.

Simply Wall St -

How Many Insiders Sold Utah Medical Products, Inc. (NASDAQ:UTMD) Shares?

Utah Medical Products Insider Transactions Over The Last Year. … In total, Utah Medical Products insiders sold more than they bought over the last year. … It is certainly not great to see that insiders have sold shares in the company

Simply Wall St -

Are Utah Medical Products, Inc.’s (NASDAQ:UTMD) High Returns Really That Great?

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … What is Return On Capital Employed (ROCE)? … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.

Simply Wall St -

Should You Worry About Utah Medical Products Inc's (NASDAQ:UTMD) CEO Pay Cheque?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Kevin Cornwell's Compensation Compare With Similar Sized Companies. … According to our data, Utah Medical Products Inc has a market capitalization of US$346m, and pays its CEO total annual compensation worth US$501k.

Simply Wall St -

How Much Of Utah Medical Products Inc (NASDAQ:UTMD) Do Insiders Own?

The big shareholder groups in Utah Medical Products Inc (NASDAQ:UTMD) have power over the company. … Utah Medical Products is a smaller company with a market capitalization of US$325m, so it may still be flying under the radar of many institutional investors. … Check out our latest analysis for Utah Medical Products

Simply Wall St -

UTMD Company Info

Description

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry in the United States, Europe, and internationally. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system. It also provides umbilical vessel catheters; DIALY-NATE, a disposable peritoneal dialysis set; PALA-NATE, a silicone oral protection device; URI-CATH, a urinary drainage system; MYELO-NATE, a lumbar sampling kit; and HEMO-NATE, a disposable filter. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars and cannulae; Femcare laparoscopic instruments and accessories; and EPITOME, an electrosurgical scalpel. Further, it provides FILSHIE CLIP system, a female surgical contraception; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization; LIBERTY system to treat and control urinary incontinence in women; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other suspected abnormalities of the uterus; and LUMIN to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It markets its products to neonatal intensive care unit, labor and delivery department, women's health center in hospitals, outpatient clinics, and physician's offices. The company sells its products through customer service and sales force, independent consultants, and independent manufacturer representatives. Utah Medical Products, Inc. was founded in 1978 and is headquartered in Midvale, Utah.

Details
Name: Utah Medical Products, Inc.
UTMD
Exchange: NasdaqGS
Founded: 1978
$325,728,375
3,722,610
Website: http://www.utahmed.com
Address: Utah Medical Products, Inc.
7043 South 300 West,
Midvale,
Utah, 84047,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS UTMD Common Stock Nasdaq Global Select US USD 01. Dec 1982
Number of employees
Current staff
Staff numbers
173
Utah Medical Products employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 23:47
End of day share price update: 2019/04/23 00:00
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.